This content is for informational purposes only and is not a substitute for professional advice.
Glycine is best tested as a narrow sleep-quality experiment, with missed timing and next-day sedation logged as carefully as bedtime.
Methodology
The protocol prioritizes subjective sleep quality, sleep onset, nighttime awakenings, and next-day alertness. Wearable sleep stages can be context, but they should not decide the trial alone.
| Metric | Primary use | Failure signal |
|---|---|---|
| Sleep quality | Main endpoint | No sustained change |
| Sleep latency | Secondary endpoint | Bedtime drift confounds result |
| Awakenings | Secondary endpoint | Alcohol or late meals confound |
| Next-day alertness | Safety endpoint | Morning grogginess |
| GI tolerance | Practical endpoint | Nausea or loose stool |
Protocol
| Phase | Rule |
|---|---|
| Baseline | 14 nights with stable caffeine and alcohol |
| Active | 2-4 weeks at the same pre-bed timing |
| Dose | Use a conservative label dose; do not combine with new sedatives |
| Review | Compare weekly averages |
| Stop | Excess sedation, allergic symptoms, severe GI effects |
Safety notes
People using sedatives, alcohol heavily, psychiatric medications, seizure medications, or diabetes medication should ask a clinician before testing glycine. Sleep apnea symptoms, severe insomnia, or unsafe sleepiness need medical review.
Sources
This article is educational and does not replace medical advice.